stockrowZymeworks Inc.
ZYME Healthcare Biotechnology
Zymeworks Inc.’s revenue for fiscal 2025 (year ended December 2025) was $106.0 million, up 38.9% from fiscal 2024.
- Revenue
- −90.6%
- EPS
- −2,166.7%
- Free cash flow
- −385.5%
Quarter to June 2026, against a year earlier
Follow ZYME
Alert me
Zymeworks Inc. (ZYME) EV/FCF
As of 5 November 2026, Zymeworks Inc. (ZYME) trades at a EV/FCF of −15.1×. Over the past ten years it has ranged from −355× (September 2019) to 36.5× (October 2018); the current reading is higher than 23% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | −49.7× | — |
| FY2024 | −8.0× | — |
| FY2023 | −2.9× | — |
| FY2022 | 0.2× | — |
| FY2021 | −3.0× | — |
| FY2020 | −12.4× | — |
| FY2019 | −14.6× | — |
| FY2018 | 11.1× | — |
| FY2017 | −29.4× | — |
| FY2016 | −3.2× | — |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Jun 2026 | −13.5× | — |
| Mar 2026 | −19.3× | — |
| Dec 2025 | −49.7× | — |
| Sep 2025 | −16.1× | — |
| 38 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| ZYME Zymeworks Inc. | −15.1× |
| COAG Hemab Therapeutics Holdings, Inc. compare | −12.6× |
| IMNM Immunome, Inc. compare | −7.0× |
| VERA Vera Therapeutics, Inc. compare | −5.2× |
| BHVN Biohaven Ltd. compare | −4.5× |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | 0.6× |
| AUPH Aurinia Pharmaceuticals Inc compare | 9.7× |
| SEPN Septerna, Inc. compare | 15.2× |
| VCEL Vericel Corporation compare | 42.8× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on ZYME
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement